Pfizer, Shanghai Pharma sign MoU to expand business in China

The partnership is intended to leverage both companies’ strengths, matching Pfizer‘s global capabilities in developing medicines with Shanghai Pharmaceutical’s capabilities and reach in the China market.

The companies are currently exploring a potential cooperation for the registration, commercialization and distribution in China of an innovative Pfizer product.

In addition, the companies plan to explore future cooperation opportunities, including further distribution and commercialization, research and development activities, manufacturing and equity investment opportunities.

The companies also expect to strengthen their existing cooperation for the promotion of Pfizer’s Prevenar (7-valent) a pneumococcal conjugate vaccine, approved for use in China for active immunization of infants and toddlers for the prevention of invasive diseases caused by the bacterium Streptococcus pneumonia.

Pfizer Emerging markets and Established products president and general manager David Simmons said their intent to explore a range of business opportunities with Shanghai Pharmaceutical is an example of their commitment to expand their presence in China in collaboration with the local industry.